These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32295453)

  • 21. Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide.
    Shafran SD; Di Perri G; Esser S; Lelièvre JD; Parczewski M
    HIV Med; 2019 Jun; 20 Suppl 7():1-16. PubMed ID: 31099116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting.
    Kauppinen KJ; Kivelä P; Sutinen J
    AIDS Patient Care STDS; 2019 Dec; 33(12):500-506. PubMed ID: 31742421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection.
    Yilmaz A; Mellgren Å; Fuchs D; Nilsson S; Blennow K; Zetterberg H; Gisslén M
    Infect Dis (Lond); 2019; 51(11-12):838-846. PubMed ID: 31556765
    [No Abstract]   [Full Text] [Related]  

  • 24. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
    Fung HB; Stone EA; Piacenti FJ
    Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction.
    Lee SS; Havens JP; Sayles HR; O'Neill JL; Podany AT; Swindells S; Scarsi KK; Bares SH
    BMC Infect Dis; 2018 Jul; 18(1):310. PubMed ID: 29980192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter?
    Vergori A; Gagliardini R; Gianotti N; Gori A; Lichtner M; Saracino A; De Vito A; Cascio A; Di Biagio A; Monforte AD; Antinori A; Cozzi-Lepri A;
    Int J Antimicrob Agents; 2020 Dec; 56(6):106154. PubMed ID: 32919008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials.
    Pilkington V; Hughes SL; Pepperrell T; McCann K; Gotham D; Pozniak AL; Hill A
    AIDS; 2020 Dec; 34(15):2259-2268. PubMed ID: 33048869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections.
    De Clercq E
    Biochem Pharmacol; 2018 Jul; 153():2-11. PubMed ID: 29225131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
    Hermansson L; Yilmaz A; Price RW; Nilsson S; McCallister S; Makadzange T; Das M; Zetterberg H; Blennow K; Gisslen M
    PLoS One; 2019; 14(12):e0226276. PubMed ID: 31826005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.
    De Clercq E
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emtricitabine + tenofovir alafenamide for the treatment of HIV.
    Corado KC; Daar ES
    Expert Opin Pharmacother; 2017 Mar; 18(4):427-432. PubMed ID: 28151023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tenofovir disoproxil fumarate.
    Grim SA; Romanelli F
    Ann Pharmacother; 2003 Jun; 37(6):849-59. PubMed ID: 12773076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.
    Mikula JM; Manion MM; Maldarelli F; Suarez LM; Norman-Wheeler JF; Ober AG; Dewar RL; Kopp JB; Lane HC; Pau AK
    Antivir Ther; 2016; 21(6):553-558. PubMed ID: 26954372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translation of clinical trial data to changes in clinical practice: rapid transition from tenofovir disoproxil fumarate to tenofovir alafenamide-based therapies in a Sydney HIV clinic.
    Smith DE; Tom M; Bowden BH
    Int J STD AIDS; 2018 Sep; 29(10):1011-1013. PubMed ID: 29621950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
    Karris MY
    AIDS Res Hum Retroviruses; 2017 Jul; 33(7):718-722. PubMed ID: 28403627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.
    Ogbuagu O
    Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1113-1126. PubMed ID: 27797606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
    Angione SA; Cherian SM; Özdener AE
    J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
    Margot NA; Liu Y; Miller MD; Callebaut C
    Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.